CONVENTIONAL DRUG THERAPY IN INFLAMMATORY BOWEL DISEASE

Adler, 1990, The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis, Am J Gastroenterol, 85, 717 Anthonisen, 1974, The clinical effect of salazosulphapyridine (salazopyrin) in Crohn’s disease, Scand J Gastroenterol, 9, 549, 10.1080/00365521.1974.12096873 Arndt, 1994, Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules, Gastroenterology, 106, 1271, 10.1016/0016-5085(94)90019-1 Azad Khan, 1980, Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis, Gut, 21, 232, 10.1136/gut.21.3.232 Azad Khan, 1977, An experiment to determine the active therapeutic moiety of sulphasalazine, Lancet, 2, 892, 10.1016/S0140-6736(77)90831-5 Baron, 1962, Sulphasalazine and salicylazosulpha-dimidine in ulcerative colitis, Lancet, 1, 1094, 10.1016/S0140-6736(62)92080-9 Bernstein, 1994, Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity, Dig Dis Sci, 39, 1638, 10.1007/BF02087769 Biddle, 1988, 5-aminosalicylic acid enemas: Effective agent in maintaining remission in left-sided ulcerative colitis, Gastroenterology, 94, 1075, 10.1016/0016-5085(88)90569-0 Blichfeldt, 1978, Metronidazole in Crohn’s disease: A double blind cross-over clinical trial, Scand J Gastroenterol, 13, 123, 10.3109/00365527809179816 Brogan, 1985, The effect of 6-mercaptopurine on natural killer-cell activities in Crohn’s disease, J Clin Immunol, 5, 204, 10.1007/BF00915512 Brogan, 1984, Effects of 6-MP on the impaired in vivo humoral responsiveness in Crohn’s disease, Gastroenterology, 86 Campieri, 1987, Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis, Dig Dis Sci, 32, 67S, 10.1007/BF01312467 Campieri, 1989, 5-aminosalicylic acid suppositories in the management of ulcerative colitis, Dis Colon Rectum, 32, 398, 10.1007/BF02563691 Campieri, 1986, Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis, Dis Colon Rectum, 29, 108, 10.1007/BF02555391 Chapman, 1992, Distribution of mesalamine enemas in patients with active distal ulcerative colitis, Mayo Clin Proc, 67, 245, 10.1016/S0025-6196(12)60100-1 Danish 5-ASA Group, 1987, Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis: A randomized, double-blind multicenter trial, Dig Dis Sci, 32, 598, 10.1007/BF01296159 D’Arenzo, 1990, 5-aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis, Dis Colon Rectum, 5, 394 Dick, 1964, Controlled trial of sulphasalazine in the treatment of ulcerative colitis, Gut, 5, 437, 10.1136/gut.5.5.437 Dissanayake, 1973, A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin), Gut, 14, 923, 10.1136/gut.14.12.923 Elion, 1967, Biochemistry and pharmacology of purine analogues, Fed Proc, 26, 898 Ewe, 1993, Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease, Gastroenterology, 105, 367, 10.1016/0016-5085(93)90709-L Flavell Matts, 1960, Local treatment of ulcerative colitis with prednisolone-21-phosphate enemata, Lancet, 1, 517, 10.1016/S0140-6736(60)90450-5 Florent, 1992, Placebo-controlled trial of Claversal in the prevention of early endoscopic relapse after “curative” resection for Crohn’s disease, Gastroenterology, 102, A623 1994 Gendre, 1993, Oral mesalamine (Pentasa) as maintenance treatment in Crohn’s disease: A multicenter placebo-controlled study, Gastroenterology, 104, 435, 10.1016/0016-5085(93)90411-5 Gilat, 1989, A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis, J Clin Gastroenterol, 11, 392, 10.1097/00004836-198908000-00008 Gilat, 1987, A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis, J Clin Gastroenterol, 9, 415, 10.1097/00004836-198708000-00011 Gionchetti, 1990, Pentasa in maintenance treatment of ulcerative colitis, Gastroenterology, 98, 251, 10.1016/0016-5085(90)91334-3 Greenfield, 1993, Review article: The mode of action of the aminosalicylates in inflammatory bowel disease, Aliment Pharmacol Ther, 7, 369, 10.1111/j.1365-2036.1993.tb00110.x Grove, 1977, Suppression of cell-mediated immunity by metronidazole, Int Arch Allergy Appl Immun, 54, 422, 10.1159/000231857 Hanauer, 1993, Long-term management of Crohn’s disease with mesalamine capsules (Pentasa), Am J Gastroenterol, 88, 1343 Heatley, 1978, Eosinophils in the rectal mucosa: A simple method of predicting the outcome of ulcerative proctocolitis?, Gut, 20, 787, 10.1136/gut.20.9.787 Hippocrates, 1988, Affections, vol V, 47 Ireland, 1988, Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis, Gut, 29, 835, 10.1136/gut.29.6.835 Kaplan, 1975, A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis, Gastroenterology, 69, 91, 10.1016/S0016-5085(19)32640-X Kirsner, 1957, The use of ACTH, cortisone, hydrocortisone and related compounds in the management of ulcerative colitis, Am J Med, 22, 264, 10.1016/0002-9343(57)90010-4 Korelitz, 1985, Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease, Dig Dis Sci, 30, 58, 10.1007/BF01318372 Kornbluth, 1993, Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis, J Clin Gastroenterol, 16, 215, 10.1097/00004836-199304000-00010 Lennard-Jones, 1960, An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis, Gut, 1, 217, 10.1136/gut.1.3.217 Lennard-Jones, 1965, Prednisone as maintenance treatment for ulcerative colitis in remission, Lancet, 1, 188, 10.1016/S0140-6736(65)90973-6 Mahida, 1990, Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease, Digestion, 45, 88, 10.1159/000200228 Malchow, 1984, European cooperative Crohn’s disease study (ECCDS): Results of drug treatment, Gastroenterology, 86, 249, 10.1016/0016-5085(84)90409-8 Markowitz, 1990, Long-term 6-mercaptopurine treatment in adolescents with Crohn’s disease, Gastroenterology, 99, 1347, 10.1016/0016-5085(90)91160-8 McLeod, 1994, Delayed recurrence following surgery for Crohn’s disease, Gastroenterology, 104, A733 Messori, 1994, Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: A meta-analysis, Am J Gastroenterol, 89, 692 Meyer, 1983, Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis, Gastroenterology, 85, 351, 10.1016/0016-5085(83)90323-2 Miner, 1994, The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis, Gastroenterology, 106, A736 Misiewicz, 1965, Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis, Lancet, 1, 185, 10.1016/S0140-6736(65)90972-4 Moertel, 1959, A critical analysis of the use of salicylazosulfapyridine in chronic ulcerative colitis, Ann Intern Med, 51, 879, 10.7326/0003-4819-51-5-879 Morrison, 1952, Results of treatment of ulcerative colitis with salicylazosulfapyridine, Gastroenterology, 21, 133, 10.1016/S0016-5085(52)80128-3 Moss, 1978, Radiologic and clinical assessment of broad-spectrum antibiotic therapy in Crohn’s disease, AJR Am J Roentgenol, 131, 787, 10.2214/ajr.131.5.787 Mulder, 1988, Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis, Gastroenterology, 95, 1449, 10.1016/S0016-5085(88)80061-1 O’Brien, 1991, Use of azathioprine or 6-mercaptopurine in the treatment of Crohn’s disease, Gastroenterology, 101, 39, 10.1016/0016-5085(91)90457-V O’Donaghue, 1978, Double-blind withdrawal trial of azathioprine as maintenance treatment of Crohn’s disease, Lancet, 2, 955, 10.1016/S0140-6736(78)92524-2 Peppercorn, 1993, Is there a role for antibiotics as primary therapy in Crohn’s ileitis?, J Clin Gastroenterol, 17, 235, 10.1097/00004836-199310000-00013 Petitjean, 1992, Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis, Aliment Pharmacol Ther, 6, 351, 10.1111/j.1365-2036.1992.tb00056.x Powell-Tuck, 1977, A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis, Scand J Gastroenterol, 12, 971, 10.3109/00365527709181359 Prantera, 1994, Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn’s disease: Results of an open study, J Clin Gastroenterol, 19, 79, 10.1097/00004836-199407000-00019 Present, 1980, Treatment of Crohn’s disease with 6-mercaptopurine: A long-term, randomized, double-blind study, N Engl J Med, 302, 981, 10.1056/NEJM198005013021801 Present, 1989, 6-mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity, Ann Intern Med, 111, 641, 10.7326/0003-4819-111-8-641 Rasmussen, 1987, 5-aminosalicylic acid in the treatment of Crohn’s disease: A 16-week double-blind, placebo-controlled, multicentre study with Pentasa, Scand J Gastroenterol, 22, 877, 10.3109/00365528708991929 Rijk, 1991, Sulphazalazine and prednisone compared with sulphasalazine for treating active Crohn disease: A double-blind, randomized, multicentre trial, Ann Intern Med, 113, 445, 10.7326/0003-4819-114-6-445 Rijk, 1992, Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: A prospective, double-blind, randomized multicenter study, Am J Gastroenterol, 87, 438 Riley, 1988, Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis, Gastroenterology, 94, 1383, 10.1016/0016-5085(88)90677-4 Rutgeerts, 1992, A placebo controlled trial of metronidazole for recurrence prevention of Crohn’s disease after resection of the terminal ileum, Gastroenterology, 102, A688 Salomon, 1992, How effective are current drugs for Crohn’s disease? A meta-analysis, J Clin Gastroenterol, 14, 211, 10.1097/00004836-199204000-00006 Singleton, 1993, Mesalamine capsules for the treatment of active Crohn’s disease: Results of a 16-week trial, Gastroenterology, 104, 1293, 10.1016/0016-5085(93)90337-C Steinhart, 1990, Azathioprine therapy in chronic ulcerative colitis, J Clin Gastroenterol, 12, 271, 10.1097/00004836-199006000-00007 Sturgeon, 1993, Exacerbation of chronic ulcerative colitis with mesalamine, Gastroenterology, 104, A785 Summers, 1979, National cooperative Crohn’s disease study: Results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 Sutherland, 1987, 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis, Gastroenterology, 92, 1894, 10.1016/0016-5085(87)90621-4 Sutherland, 1993, Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis, Ann Intern Med, 118, 540, 10.7326/0003-4819-118-7-199304010-00009 Sutherland, 1991, Double blind, placebo controlled trial of metronidazole in Crohn’s disease, Gut, 32, 1071, 10.1136/gut.32.9.1071 Svartz, 1942, Salazopyrin, a new sulfanilamide preparation, Acta Med Scand, 110, 577, 10.1111/j.0954-6820.1942.tb06841.x Svartz, 1954, The treatment of ulcerative colitis, Gastroenterology, 26, 26, 10.1016/S0016-5085(54)80065-5 Tawfik, 1990, Influence of new quinolones on normal immune capabilities, J Chemother, 2, 300, 10.1080/1120009X.1990.11739033 Thomas, 1991, Evaluation of interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model, Agents Actions, 34, 187, 10.1007/BF01993274 Truelove, 1958, Treatment of ulcerative colitis with local hydrocortisone semisuccinate sodium: A report on a controlled therapeutic trial, BMJ, 2, 1072, 10.1136/bmj.2.5104.1072 Truelove, 1955, Cortisone in ulcerative colitis: Final report on a therapeutic trial, BMJ, 2, 1041, 10.1136/bmj.2.4947.1041 Truelove, 1959, Cortisone and corticotrophin in ulcerative colitis, BMJ, 1, 387, 10.1136/bmj.1.5119.387 Turunen, 1994, A double-blind, placebo controlled six-month ciprofloxacin treatment improves prognosis in ulcerative colitis, Gastroenterology, 106, A786 Turunen, 1993, Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn’s disease, Gastroenterology, 104, A793 Ursing, 1982, A comparative study of metronidazole and sulfasalazine for active Crohn’s disease: The cooperative Crohn’s disease study in Sweden, Gastroenterology, 83, 550, 10.1016/S0016-5085(82)80189-3 Van Buul, 1989, Retrograde spread of therapeutic enemas in patients with inflammatory bowel disease, Hepatogastroenterology, 36, 199 Van Hees, 1980, Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulfasalazine, Gut, 21, 632, 10.1136/gut.21.7.632 Van Hees, 1981, Effect of sulphasalazine in patients with active Crohn’s disease: A controlled double-blind study, Gut, 22, 404, 10.1136/gut.22.5.404 Walsh, 1991, The eosinophil in inflammatory bowel disease, Scand J Gastroenterol, 26, 1217, 10.3109/00365529108998617 Watkinson, 1958, Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: A controlled trial employing restricted sequential analysis, BMJ, 2, 1077, 10.1136/bmj.2.5104.1077 Zetzel, 1958, ACTH and adrenalcorticosteroids in the treatment of ulcerative colitis, Am J Dig Dis, 12, 916, 10.1007/BF02231380